The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics

Alexandra Lucas, Liying Liu, Erbin Dai, Ilze Bot, Kasinath Viswanathan, Ganesh Munuswamy-Ramunujam, Jennifer A. Davids, Mee Y. Bartee, Jakob Richardson, Alexander Christov, Hao Wang, Colin Macaulay, Mark Poznansky, Robert Zhong, Leslie Miller, Erik Biessen, Mary Richardson, Collin Sullivan, Richard Moyer, Mark HattonDavid A. Lomas, Grant McFadden

Research output: Chapter in Book/Report/Conference proceedingChapter

29 Scopus citations

Abstract

Serine proteinase inhibitors, also called serpins, are an ancient group ing of proteins found in primitive organisms from bacteria, protozoa and horseshoe crabs and thus likely present at the time of the dinosaurs. up to all mammals living today. The innate or inflammatory immune system is also an ancient metazoan regulatory system. providing the first line ofdefense against infection or injury. The innate inflammatory defense response evolved long before acquired. antibody dependent immunity. Viruses have developed highlyeffective stratagems that undermine and block a wide variety ofhost inflammatory and immune responses. Some of the most potent of these immune modifying strategies utilize serpins that have also been developed over millions ofyears. including the hijacking by some viruses for defense against host immune attacks . Serpins represent up to 2-10 percent ofcirculating plasma proteins. regulating actions as wide ranging as thrombosis. inflammation. blood pressure control and even hormone transport. Targeting serpin-regulated immune or inflammatory pathways makes evolutionary sense for viral defense and many of these virus-derived inh ibitory proteins have proven to be highly effective.working at very low concentrations-even down to the femptomolar to picomolar range. We are studying these viral anti-inflammatory proteins as a new class ofimmunomodulatory therapeutic agents derived from their native viral source. One such viral serpin, Serp-I is now in clinical trial (conducted by VIRON Therapeutics, Inc.) for acute unstable coronary syndromes (unstable angina and small heart attacks), representing a 'first in class' therapeutic study. Several other viral serpins are also currently under investigation as anti-inflammatory or anti-immune therapeutics. This chapter describes these original studies and the ongoing analysis ofviral serpins as a new class ofvirus-derived immunotherapeutic.

Original languageEnglish (US)
Title of host publicationPathogen-Derived Immunomodulatory Molecules
EditorsPadraic Fallon
Pages132-156
Number of pages25
DOIs
StatePublished - Dec 1 2009
Externally publishedYes

Publication series

NameAdvances in Experimental Medicine and Biology
Volume666
ISSN (Print)0065-2598

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Lucas, A., Liu, L., Dai, E., Bot, I., Viswanathan, K., Munuswamy-Ramunujam, G., Davids, J. A., Bartee, M. Y., Richardson, J., Christov, A., Wang, H., Macaulay, C., Poznansky, M., Zhong, R., Miller, L., Biessen, E., Richardson, M., Sullivan, C., Moyer, R., ... McFadden, G. (2009). The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics. In P. Fallon (Ed.), Pathogen-Derived Immunomodulatory Molecules (pp. 132-156). (Advances in Experimental Medicine and Biology; Vol. 666). https://doi.org/10.1007/978-1-4419-1601-3_11